Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Indhold leveret af Dr Neil Love. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Dr Neil Love eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
Breast Cancer | Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer (Companion Faculty Lecture)
MP4•Episode hjem
Manage episode 441823909 series 2513286
Indhold leveret af Dr Neil Love. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Dr Neil Love eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics:
- Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00)
- ASCENT trial: Survival advantage with sacituzumab govitecan versus physician’s choice of chemotherapy for patients with relapsed/refractory TNBC (2:49)
- Treatment-associated side effects with sacituzumab govitecan (5:32)
- Activity of sacituzumab govitecan irrespective of TROP2 expression level and in patients with brain metastases (6:48)
- Ongoing Phase III studies evaluating sacituzumab govitecan in earlier lines of treatment (eg, ASCENT-03, ASCENT-04) (8:51)
- Efficacy and tolerability of trastuzumab deruxtecan in patients with HER2-low and HER2-ultralow metastatic breast cancer (10:26)
- Activity and ongoing investigations of other novel agents and strategies for mTNBC (20:05)
1364 episoder
MP4•Episode hjem
Manage episode 441823909 series 2513286
Indhold leveret af Dr Neil Love. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Dr Neil Love eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics:
- Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00)
- ASCENT trial: Survival advantage with sacituzumab govitecan versus physician’s choice of chemotherapy for patients with relapsed/refractory TNBC (2:49)
- Treatment-associated side effects with sacituzumab govitecan (5:32)
- Activity of sacituzumab govitecan irrespective of TROP2 expression level and in patients with brain metastases (6:48)
- Ongoing Phase III studies evaluating sacituzumab govitecan in earlier lines of treatment (eg, ASCENT-03, ASCENT-04) (8:51)
- Efficacy and tolerability of trastuzumab deruxtecan in patients with HER2-low and HER2-ultralow metastatic breast cancer (10:26)
- Activity and ongoing investigations of other novel agents and strategies for mTNBC (20:05)
1364 episoder
Alle episoder
×Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.